Literature DB >> 35422249

Sex-Based Differences in Heart Failure: JACC Focus Seminar 7/7.

Sadiya S Khan1, Lauren B Beach2, Clyde W Yancy3.   

Abstract

Sex-based differences exist in risk, symptoms, and management of heart failure (HF). Women have a higher incidence of HF with preserved ejection fraction compared with men. This may be partially caused by the cardiovascular effects of estrogen and sex-specific risk factors (eg, adverse pregnancy outcomes, premature menopause). Key gaps exist in understanding of gender-based differences in HF, which is a distinctly different concept than sex-based differences. Although evidence-based therapies for HF are available, only limited data address sex-specific efficacy, and no data address gender-based efficacy. Persistent shortcomings in representation of women and gender minority participants in clinical trials limit an actionable database. A comprehensive roadmap to close the sex/gender-based gap in HF includes the following: 1) sex/gender-specific personalized prevention; 2) sex/gender-neutral implementation of evidence-based therapies; and 3) sex/gender-appropriate policy-level initiatives to spur research assessing sex/gender-specific causes of HF; enhance sex/gender-specific subgroup reporting; and promote community engagement of these important patient cohorts.
Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  gender; heart failure; sex

Mesh:

Year:  2022        PMID: 35422249     DOI: 10.1016/j.jacc.2022.02.013

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  2 in total

Review 1.  Sex, gender, and subclinical hypertensiveorgan damage-heart.

Authors:  Cesare Cuspidi; Elisa Gherbesi; Carla Sala; Marijana Tadic
Journal:  J Hum Hypertens       Date:  2022-08-27       Impact factor: 2.877

2.  Uncovering the Genetic Etiology of the (Posttherapy) Broken Heart.

Authors:  Martha S Linet; Graça M Dores; Sharon A Savage
Journal:  J Natl Cancer Inst       Date:  2022-08-08       Impact factor: 11.816

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.